Vectura, Inspira team up to develop inhaled COVID-19 drug
7th May 2021
Contract development and manufacturing organisation (CDM) Vectura Group and Inspira Pharmaceuticals, a new UK-based company focused on developing therapies for respiratory and infectious diseases, have teamed up to develop an inhaled formulation of the latter s lead drug candidate for the treatment of COVID-19.
Inspira’s research focuses on proprietary IPX formulations, which are based on processed and purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 virus in vitro. The IPX technology platform has additional potential applications in other lung infections and treatment of biofilms associated with respiratory disease.
Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19
Chippenham, UK and London, UK – 6 May 2021: Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies for respiratory and infectious diseases, today announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the treatment of COVID-19.
Inspira’s research focuses on proprietary IPX formulations, which are based on processed and purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 virus
in vitro. The IPX technology platform has additional potential applications in other lung infections and treatment of biofilms associated with respiratory disease.